** Shares of drug developer Arvinas ARVN.O fall 3% to $6.98
** Brokerage Leerink lowers ARVN's PT to $9 from $10; cuts rating to "market perform" from "outperform"
** Leerink cuts ARVN rating due to pending visibility on whether it can unlock "vepdegestrant's fundamental value and create a compelling investment thesis"
** ARVN and Pfizer's PFE.N experimental treatment, vepdegestrant, delayed progression of breast cancer by more than three months compared to AstraZeneca's AZN.L Faslodex in patients with ESR1 mutations
** Commitment from PFE in developing vepdegestrant combinations remains uncertain, and it is unlikely another partnership strategy could materialize - Leerink
** New rating reflects uncertainties on the market opportunity and path forward around vepdegestrant as well as the early stage of the pipeline - brokerage
** ARVN has fallen 62.4% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。